Overview

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer

Status:
Not yet recruiting
Trial end date:
2023-01-31
Target enrollment:
0
Participant gender:
Female
Summary
To evaluate the diagnostic performance of Tc99m sestamibi (MBI) compared to breast MRI in women who are at high risk for developing breast cancer. To assess the relationship of tumor size, histologic subtype and location of lesion and how it affects lesion conspicuity and sensitivity in MBI detected cancers.
Phase:
Early Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Technetium Tc 99m Sestamibi
Criteria
Inclusion Criteria:

- The subjects to be studied will include female patients ages 18 and older of any race,
identified as carrying an elevated risk for breast cancer referred to MDACC.

- High risk may be defined as having a calculated lifetime risk >20%, histopathology of
lobular neoplasia or atypical ductal hyperplasia, atypia NOS or a genetic mutation
known to predispose the patient to breast cancer.

Exclusion Criteria:

- Subjects who are pregnant will be excluded as MBI exam involves injection of
radioactive tracer

- contrast enhanced MRI involves gadolinium injection, both of which are contraindicated
during pregnancy.